CLINICAL EFFICACY OF THE ANTIVIRAL DRUG REMDESIVIR IN THE COMPREHENSIVE TREATMENT OF PATIENTS WITH COVID-19
Introduction. Currently, one of the promising antiviral drugs for the treatment of COVID-19 is remdesivir. For a final decision on the inclusion of this drug in the international recommendations for the treatment of COVID-19, further studies are needed to evaluate its effectiveness and safety in patients with COVID-19.
The aim of the study is to study the clinical efficacy of remdesivir in the comprehensive therapy of patients with moderate severity of COVID-19.
Materials and methods of research. In the study data was analyzed from 80 medical records of an inpatient patient with a moderate form of COVID-19.
The work was carried out in accordance with the task of the Ministry of Health of the Republic of Kazakhstan as part of a clinical study which is an open retrospective study to evaluate the effectiveness of remdesivir in the comprehensive treatment of patients with COVID-19. The experimental group (the main group) consisted of 40 patients with a moderate form of COVID-19 were prescribed remdesivir at a dose of 200 mg IV on 1st day, then 100 mg IV daily, for a total of 5-7 days in addition to standard therapy. The comparison group (control group) consisted of 40 patients who received pathogenetic and symptomatic therapy without remdesivir in accordance with the clinical protocol.
Statistical processing of the obtained data was carried out by methods of descriptive statistics, using a comparative analysis by the T-test Student method, frequency analysis, Chi-square calculations with the IBM SPSS Statistics 20.0 and Jamovi programs.
Results and discussion. The study showed that an early start of antiviral therapy with Remdesivir compared to standard therapy without an antiviral drug in patients with a moderate form of COVID-19 is associated with a statistically significant clinical improvement and a large percentage of virus elimination from the upper respiratory tract proved by molecular genetic study.
In the group of patients receiving remdesivir, complete remission of the disease with normalization of body temperature and no complaints for 7 days of hospitalization was significantly more often than in the comparison group.Antiviral therapy with the remdesivir was prescribed to patients with concomitant pathology (diabetes mellitus, obesity, arterial hypertension), which is a risk factor for a severe, unfavorable course of the disease.There were no cases of deterioration of the patient's condition due to the progression of the infectious process during the use of remdesivir.Whereas in the control group, 10% of patients had progression of the disease with the development of complications. All these patients had risk factors for the development of severe COVID-19.
Conclusion.The results obtained showed that the remdesivir is an effective antiviral drug in the comprehensive treatment of COVID-19 coronavirus infection of moderate severity.Early administration of the drug in patients with a moderate form of the disease can prevent the progression of the disease to a more severe condition and the development of complications that require additional medical interventions. This drug can be used in patients with concomitant pathologies that are risk factors for a severe, unfavorable course of coronavirus infection caused by SARS-CoV-2.
Azhar Giniyat1, Sholpan A. Kulzhanova2, https://orcid.org/000-0002-4118-4905
Gulnara T. Tuleshova2, https://orcid.org/0000-0002-7309-5165
Maiya E. Konkayeva2, https://orcid.org/0000-0002-1634-3855
Zauresh K. Smagulova2,
Nazira Nu. Beisenbieva2,
Aigul M. Utegenova2, https://orcid.org/ 0000-0002-5777-3747
Gulsimzhan O. Turebaeva2 ,
Gaukhar A. Nurakhmetova2, https://orcid.org/ 0000-0002-3279-9350
Aidos Bolatov2, https://orcid.org/0000-0002-5390-4623
1 Ministry of Health of the Republic of Kazakhstan,
Nur-Sultan, Republic of Kazakhstan;
2 Non-profit JSC “Astana Medical University”,
Nur-Sultan, Republic of Kazakhstan.
1. Pascarella G., Strumia A., Piliego C., Bruno F., Del Buono R. and Costa F. COVID-19 diagnosis and management: a comprehensive review. J Int Med 2020; 288(2): 192 206.
2. Eroglu E., Toprak G. Overview of favipiravir and remdesivir treatment for COVID-19. International Journal of Pharmaceutical Sciences and Research, 2021; Vol. 12(4): 1950-1957.
3. Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K. and Yuan S. Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9(1): 221-36.
4. Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K. and Singh A.: Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020; 1866(10): 165878.
5. Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K. and Singh A.: Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020; 1866(10): 165878.
6. Chen Y., Liu Q. and Guo D.: Emerging coronaviruses: Genome structure, replication and pathogenesis. J Med Virol 2020; 92(4): 418-23.
7. Fung T.S. and Liu D.X. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol 2019; 73: 529-57.
8. Kortepeter M.G., Dierberg K., Shenoy E.S. and Cieslak T.J. Medical Countermeasures Working Group of the National Ebola T, Education Center's Special Pathogens Research N. Marburg virus disease: A summary for clinicians. Int J Infect Dis 2020; 99: 233-42.
9. Siegel D., Hui H.C., Doerffler E., Clarke M.O., Chun K. and Zhang L.: Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo [2,1-f][triazin-4-amino] Adenine CNucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem 2017; 60(5): 1648-61.
10. Tchesnokov E.P., Feng J.Y., Porter D.P. and Gotte M.: Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA polymerase by Remdesivir. Viruses 2019; 11(4): 326.
11. Pardo J., Shukla AM, Chamarthi G and Gupte A: The journey of remdesivir: from Ebola to COVID-19. Drugs Context 2020; 9.
12. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269.
13. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med 2020.
14. Beigel J.H., Tomashek K.M., Dodd L.E., et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020 Nov 5;383(19):1813-1826.
15. Wang Y., Zhang D., Du G., Du R., Zhao J. and Jin Y.: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
16. Awadhesh Kumar Singh 1, Akriti Singh 2, Ritu Singh 3, Anoop Misra Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020 Jul-Aug;14(4):641-648.
17. Sarah C J Jorgensen 1, Razieh Kebriaei 2, Linda D Dresser Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. 2020 Jul;40(7):659-671.
18. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E. and Castagna A.: Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382(24): 2327-36. 36.
19. Goldman J.D., Lye D.CB., Hui D.S., Marks K.M., Bruno R. and Montejano R.: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383(19): 1827-37.
20. Yang K: What Do We Know About Remdesivir Drug Interactions. Clin Transl Sci 2020; 13(5): 842-4.
21. Cao Y.C., Deng Q.X. and Dai S.X.: Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis 2020; 35: 101647.
22. Spinner C.D., Gottlieb R.L., Criner G.J., et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020;324:1048-1057.
Number of Views: 147
Category of articles:
COVID-19 - Topical Subject
Bibliography link
Giniyat A.G., Kulzhanova Sh. A., Tuleshova G.T., Konkayeva M.E., Smagulova Z. K., Beisenbieva N.Nu., Utegenova A.M., Turebaeva G.O., Nurakhmetova G.A., Bolatov A. Clinical efficacy of the antiviral drug remdesivir in the comprehensive treatment of patients with COVID-19 // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, 3 (Vol.23), pp. 6-15. doi 10.34689/SH.2021.23.3.001Related publications:
IMMUNOLOGICAL CHANGES IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2
EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
APPLICATION OF ARTIFICIAL INTELLIGENCE IN COMBATING THE COVID-19 PANDEMIC: CURRENT TRENDS AND PROSPECTS. REVIEW
CONSEQUENCES OF THE CORONAVIRUS INFECTION: THE POST-COVID SYNDROME AND MENTAL MANIFESTATIONS. LITERATURE REVIEW
FEATURES OF THE SICKNESS BEHAVIOR OF ARTERIAL HYPERTENSION AND OBESITY DURING THE PANDEMIC OF COVID-19 CORONAVIRUS. REVIEW